Do we really need yet another JAKi? COURAGE-RA RCT phIII JAK1-selective Zemprocitinib RA bDMARDs IR Primary endpoint ACR20 at wk24 79.1% vs 39.7% PBO (p<0.0001) wk24 ACR50: 55.8% vs 22.0% wk 24 DAS28-CRP ≤3.2: 67.0% vs 23.4% No new safety signal Looks very similar to other https://t.co/b0RMBWl4Xx

Low-dose blinatumomab in multidrug-resistant RA 15 pts 96h cycles CD3×CD19 T-cell engager DAS28-CRP: 4.8 → 2.4 3 mo ACR20 100% ACR50 73% ACR70 53% DAS28 remission 33% But... only transient efficacy with 93% relapse after stopping treatment Authors highlight response to https://t.co/GCS6774tJt

#EULAR2026 OP0221 Can we refine response measure in #lupusnephritis RCT? Asia Pacific cohort: construct validity of TRM-SLE definition: 1)RCT entry threshold uPCR >1g/g; 2)clinically meaningful response >50% improvement in UPCR; 3)stricter complete response UPCR<0.2g/g @RheumNow https://t.co/dlErgyFMZP

#OP0223 at #EULAR2026: Not every lupus nephritis patient may need upfront triple therapy. Using EULAR 2025 prognostic factors, triple therapy significantly improved complete renal response only in high-risk patients, supporting more precision-based treatment approach. @RheumNow https://t.co/F8Kn23YjNr

Ivarmacitinib (selective oral JAKi) in active nr-axSpA: This ph3 RCT showed that Ivarmacitinib 4mg significantly improved s/sxs & dse act vs. PBO at wk 12 (39.7% vs 24.8%; P=0.0057) and maintained until wk 24 Interesting. A new JAKi option for axSpA OPO237 @RheumNow #EULAR2026 https://t.co/bxbO8GfegP

#OP0222 at #EULAR2026: ReBioLup highlights the disconnect between proteinuria & histopathological activity in lupus nephritis. 73% of patients with persistent histologic activity at 12 months still met criteria for complete clinical response. @RheumNow https://t.co/VxgT6812VO

ASAS-SPARTAN revised #axSpA classification criteria have hug specificity (>94%) but lower sensitivity than the 2009 criteria, excluding ~27% of patients classified by the older criteria Abstr OP239 @RheumNow #EULAR2026 https://t.co/vGJN8eEKKh

#EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.” Data-driven analysis from 13 nations suggested: SLEDAI≥6 + PGA>1 + mild-moderate or severe flare (MMSf) + GC≥10 +IS. Need validation study before use @RheumNow https://t.co/K2dMSQUIgB